The DNA repair functions of PARP‐1 have been targeted for anti‐cancer effects through use of pharmacological PARP inhibitors (PARPi; Lord & Ashworth, 2008), which have been approved of ovarian cancer, and are under clinical investigation in a number of other tumor types, including prostate cancer (PCa). Here, PARP1 is linked to neoplasm.